Leonard Schleifer

Leonard Schleifer
Name	Leonard Schleifer
Birth date	1953
Birth place	Rochester, New York
Alma mater	Cornell University, Columbia University Vagelos College of Physicians and Surgeons, Harvard Medical School
Occupation	Physician, entrepreneur, executive
Years active	1980s–present
Known for	Co-founder and CEO of Regeneron Pharmaceuticals

Leonard Schleifer is an American physician, entrepreneur, and biotechnology executive best known as co-founder and chief executive officer of Regeneron Pharmaceuticals. He led the company through development of biologic therapeutics and regulatory milestones, and has been active in collaborations with academic institutions and pharmaceutical companies. Schleifer's career spans clinical neurology training, venture creation, and public advocacy on biomedical innovation.

Early life and education

Schleifer was born in Rochester, New York, and raised in a family rooted in local Rochester, New York and regional institutions. He attended Cornell University for undergraduate studies and pursued medical training at the Columbia University Vagelos College of Physicians and Surgeons and Harvard Medical School, completing residencies and fellowships associated with prominent hospitals. His early mentors and contemporaries included clinicians and researchers affiliated with Massachusetts General Hospital, Johns Hopkins Hospital, NewYork-Presbyterian Hospital, and academic networks linking Columbia University, Harvard University, and Weill Cornell Medicine. During his formative years he engaged with professional societies such as the American Academy of Neurology, the Association of American Physicians, and the National Institutes of Health research community.

Medical and pharmaceutical career

After clinical training in neurology, Schleifer transitioned into pharmaceutical entrepreneurship, interacting with established firms and translational research centers like Merck & Co., Pfizer, GlaxoSmithKline, Eli Lilly and Company, and Roche. He worked alongside figures from biotech hubs in Boston, Massachusetts and Silicon Valley, collaborating with translational groups at Massachusetts Institute of Technology, the Broad Institute, and the Dana-Farber Cancer Institute. Schleifer's early professional network included executives and scientists from Genentech, Amgen, Biogen, Genzyme, and venture partners linked to Sequoia Capital and Accel Partners. His involvement in drug development integrated regulatory frameworks administered by the Food and Drug Administration and research funding from agencies such as the National Institutes of Health and philanthropic organizations like the Howard Hughes Medical Institute.

Founding and leadership of Regeneron

In 1988 Schleifer co-founded Regeneron Pharmaceuticals and established its headquarters in Tarrytown, New York before expansion to East Greenbush, New York and operations near Rensselaer County. He partnered with scientists and executives from institutions including Rockefeller University, Cold Spring Harbor Laboratory, New York University, and the Icahn School of Medicine at Mount Sinai. Under his leadership Regeneron entered strategic alliances and licensing agreements with major corporations such as Sanofi, Bayer, Teva Pharmaceutical Industries, Novartis, and Johnson & Johnson. Corporate governance interactions involved entities like the New York Stock Exchange, the Securities and Exchange Commission, and industry groups such as the Biotechnology Innovation Organization.

Major drug developments and scientific contributions

Regeneron, guided by Schleifer, developed monoclonal antibodies and biologics leveraging platforms related to VEGF pathway blockade and inflammatory cytokine modulation; collaborations referenced work from laboratories at Yale University, Stanford University, University of California, San Francisco, and University of Pennsylvania. Notable therapeutics emerged from programs addressing ophthalmology, immunology, and rare diseases, with regulatory approvals reviewed by the Food and Drug Administration, the European Medicines Agency, and health technology assessment bodies in United Kingdom and Germany. Regeneron's pipeline benefited from technologies pioneered at institutions like MIT, the Salk Institute, and Cold Spring Harbor Laboratory, and from scientific dialogues with investigators at Johns Hopkins University School of Medicine, UCSF Medical Center, and Massachusetts General Hospital. Clinical development programs included randomized controlled trials conducted at centers such as Mayo Clinic, Cleveland Clinic, and Karolinska Institutet, and involved regulatory endpoints comparable to those in approvals for therapies from Genentech and Amgen. The company advanced platform capabilities in genetic target validation informed by databases like ClinVar and consortia including the 1000 Genomes Project and the ENCODE Project.

Business strategy, philanthropy, and public engagement

Schleifer guided Regeneron's business strategy through alliances with multinational pharmaceutical firms, capital raises on public markets, and partnerships with academic translational centers including Columbia University, Harvard Medical School, and the University of Pennsylvania. Philanthropic efforts and public engagement connected the company to initiatives at institutions such as the Kennedy Center, the Metropolitan Museum of Art, regional health systems in New York State, and biomedical philanthropy networks including the Gates Foundation and the Howard Hughes Medical Institute. His public commentary has intersected with policy debates involving the National Institutes of Health, the Centers for Medicare & Medicaid Services, and legislative oversight bodies on biomedical innovation. Corporate philanthropy and collaboration programs have supported research at Cold Spring Harbor Laboratory, the New York Academy of Sciences, and education partnerships with Cornell University.

Personal life and honors

Schleifer has been recognized by industry and academic organizations, receiving awards and honors from associations such as the Biotechnology Innovation Organization, the American Academy of Neurology, and regional chambers of commerce. He has engaged with advisory boards at Harvard Medical School, Columbia University, and research institutes including The Rockefeller University and the HudsonAlpha Institute for Biotechnology. His personal affiliations connect to cultural and civic institutions in New York City, Westchester County, New York, and national networks of biomedical leaders in Washington, D.C..

Category:Living people Category:American chief executives Category:Biotechnology founders